Welch Group LLC Reduces Stake in Gilead Sciences Inc. (GILD)
Welch Group LLC reduced its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 17.0% during the second quarter, Holdings Channel reports. The fund owned 2,342 shares of the biopharmaceutical company’s stock after selling 479 shares during the period. Welch Group LLC’s holdings in Gilead Sciences were worth $195,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of GILD. BNP Paribas Arbitrage SA raised its stake in shares of Gilead Sciences by 0.4% in the second quarter. BNP Paribas Arbitrage SA now owns 2,170,640 shares of the biopharmaceutical company’s stock valued at $181,075,000 after buying an additional 8,430 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Gilead Sciences by 17.5% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,739,537 shares of the biopharmaceutical company’s stock valued at $159,794,000 after buying an additional 258,807 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock valued at $1,137,969,000 after buying an additional 161,505 shares during the last quarter. Temasek Holdings Private Ltd raised its stake in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock valued at $1,270,471,000 after buying an additional 1,035,592 shares during the last quarter. Finally, Omega Advisors Inc. acquired a new stake in shares of Gilead Sciences during the first quarter valued at approximately $47,491,000. 78.00% of the stock is owned by institutional investors.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.15% during midday trading on Monday, reaching $72.64. The company’s stock had a trading volume of 8,181,411 shares. The company’s 50-day moving average price is $77.72 and its 200-day moving average price is $84.20. Gilead Sciences Inc. has a 12 month low of $72.21 and a 12 month high of $111.11. The company has a market cap of $95.86 billion, a PE ratio of 6.38 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company’s revenue was down 5.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.15 EPS. On average, equities analysts anticipate that Gilead Sciences Inc. will post $11.76 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were paid a $0.47 dividend. The ex-dividend date was Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.59%. Gilead Sciences’s dividend payout ratio (DPR) is 16.56%.
Several equities research analysts recently commented on GILD shares. Royal Bank Of Canada upped their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Monday, October 3rd. Jefferies Group cut their target price on Gilead Sciences from $93.00 to $91.00 and set a “hold” rating on the stock in a research report on Wednesday, August 31st. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Monday, September 26th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $108.00 price target on shares of Gilead Sciences in a report on Wednesday, August 31st. Finally, Leerink Swann set a $112.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, September 22nd. Ten equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $103.60.
In other news, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $80.50, for a total value of $8,050,000.00. Following the completion of the sale, the insider now directly owns 4,119,727 shares in the company, valued at approximately $331,638,023.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the company’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $79.81, for a total value of $159,620.00. Following the completion of the sale, the executive vice president now owns 64,122 shares of the company’s stock, valued at $5,117,576.82. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.